Actos (Pioglitazone) Cost in Alabama 2026

What Does Pioglitazone Actually Cost in Alabama in 2026?

Generic pioglitazone runs about $15 per month at most Alabama retail pharmacies when you pay without insurance in 2026. Brand-name Actos carries a manufacturer list price near $60 per month, though almost no patient pays that figure after coupons or a savings card. The FDA approved pioglitazone in 1999 for type 2 diabetes mellitus, and the drug lost patent protection years ago, so low-cost generics now dominate the market. [1]

Retail Cash Prices by Dose

The 30 mg tablet is the most commonly dispensed strength and typically costs $12 to $16 per 30-tablet supply at Alabama chains such as Walmart, Walgreens, and CVS. The 15 mg tablet runs slightly less, and the 45 mg tablet slightly more, but the range rarely exceeds $20 per month for any strength when you use a discount card. [2]

Pioglitazone belongs to the thiazolidinedione class. It works by activating peroxisome proliferator-activated receptor gamma (PPARγ), which improves insulin sensitivity in muscle, fat, and liver tissue. [3] That mechanism also underlies its off-label use in non-alcoholic steatohepatitis (NASH), now called metabolic-associated steatohepatitis (MASH).

GoodRx and Other Discount Cards

GoodRx coupons routinely bring generic pioglitazone to $9 to $14 per month at Alabama pharmacies. RxSaver and NeedyMeds offer comparable reductions. These cards work at the point of sale and require no enrollment period. You cannot combine them with Medicaid or Medicare Part D on the same claim, but cash-pay patients can use them without restriction. [4]

Walmart $4 Generic Program

Walmart's $4 generic drug program includes pioglitazone 15 mg and 30 mg tablets. A 30-day supply costs $4, and a 90-day supply costs $10. Alabama residents with a valid prescription can access this program at any Alabama Walmart pharmacy without membership fees. [5]

Alabama Medicaid Coverage for Pioglitazone

Alabama Medicaid does not cover pioglitazone under its standard preferred drug list (PDL) for type 2 diabetes management or for off-label NASH indications as of 2026. [6] The Alabama Medicaid Agency publishes its PDL through the Pharmacy Program, which lists metformin, sulfonylureas, and select SGLT-2 inhibitors as preferred agents for diabetes. Pioglitazone is classified as non-preferred.

Prior Authorization Pathway

A prescriber can submit a prior authorization (PA) request to Alabama Medicaid. Approval requires documentation that the patient has failed or cannot tolerate at least two preferred agents. Approval rates for PA requests for non-preferred diabetes drugs in Alabama are not publicly reported, but national data suggest PA approval for thiazolidinediones runs below 40% in state Medicaid programs. [7]

CHIP and ALL Kids

The ALL Kids program (Alabama's CHIP) follows the same PDL as Alabama Medicaid for outpatient prescription drugs. Pioglitazone is not covered for pediatric patients under ALL Kids without an approved PA. Pediatric type 2 diabetes treatment guidelines from the American Diabetes Association recommend metformin and insulin as first-line agents for patients under 18, so this restriction aligns with clinical practice. [8]

Dual-Eligible Patients

Alabama residents eligible for both Medicare and Medicaid (dual eligibles) should check their Medicare Part D plan's formulary separately. Part D plans are not bound by the Alabama Medicaid PDL. Several Part D plans operating in Alabama do include generic pioglitazone on Tier 1 or Tier 2, which can reduce cost-sharing to $0 to $10 per month. [9]

Insurance Coverage for Pioglitazone in Alabama

Most commercial insurance plans available through the Alabama Health Insurance Marketplace and employer-sponsored coverage do include generic pioglitazone, typically on Tier 1 (preferred generic) with a copay of $0 to $15. Brand Actos, when covered at all, generally sits on Tier 3 or Tier 4 with copays exceeding $50 per month.

Checking Your Formulary

The fastest way to confirm coverage is to search your plan's formulary on its member portal or call the pharmacy benefits number on your insurance card. Search for "pioglitazone" rather than "Actos," because most plans list only the generic name. The National Library of Medicine's DailyMed database provides up-to-date drug information you can reference when speaking with your insurer. [10]

Step Therapy Requirements

Several Alabama commercial plans impose step therapy for pioglitazone, meaning you must try and document failure of metformin before pioglitazone is covered. Alabama enacted step-therapy override protections under Alabama Code § 27-43-1, which requires insurers to grant an override when a prescriber documents that the required step-therapy drug is contraindicated, ineffective, or causes adverse effects for the specific patient. [11]

Medicare Part D in Alabama

Generic pioglitazone appears on the formularies of most Part D plans sold in Alabama. The 2026 Medicare Part D redesign, implemented under the Inflation Reduction Act, caps out-of-pocket drug spending and may reduce or eliminate cost-sharing for Tier 1 generics in the catastrophic phase. Patients on fixed incomes should apply for the Part D Low-Income Subsidy (Extra Help), which the Social Security Administration administers. [12]

Compounded Pioglitazone in Alabama: Legality and Cost

Compounded pioglitazone is legal in Alabama when prepared by a state-licensed 503A compounding pharmacy operating under a valid prescription from a licensed prescriber. [13] The Alabama State Board of Pharmacy regulates 503A pharmacies and requires them to comply with USP standards for non-sterile compounding.

What 503A Means

A 503A pharmacy compounds drugs for individual patients based on a specific prescription. It is not a manufacturer. Compounded pioglitazone is not FDA-approved, but its preparation is federally legal under Section 503A of the Federal Food, Drug, and Cosmetic Act when the pharmacy meets state and federal requirements. [14] The FDA's current policy does not list pioglitazone on its list of drug products that may not be compounded under 503A, so compounding remains permissible.

Why Compounded Pioglitazone Is Used

Compounding allows prescribers to customize dose, eliminate certain fillers or dyes, or combine pioglitazone with other active ingredients in a single capsule. For NASH/MASH patients in clinical discussions, some prescribers combine pioglitazone with other metabolic agents in a compounded formulation. The PIVENS trial (N=247, NEJM 2010) showed pioglitazone 30 mg daily produced histologic improvement in NASH in 34% of patients versus 19% in the placebo group (P<0.001), supporting its off-label use in this population. [15]

Cost of Compounded Pioglitazone in Alabama

Compounded pioglitazone from a 503A pharmacy partnered with HealthRX may cost $0 per month for qualifying patients when covered through specific membership or program pricing. Standard 503A compounding pharmacies charge $20 to $60 per month depending on dose and formulation. Always confirm that the pharmacy holds an active Alabama State Board of Pharmacy license before filling a compounded prescription.

Telehealth Prescribing of Pioglitazone in Alabama

Alabama law permits telehealth prescribing of pioglitazone when the prescriber establishes a valid patient-provider relationship. [16] The Alabama Telehealth Act (Act 2021-76) expanded telehealth permissions and removed the requirement for an in-person visit before telehealth services can begin, provided the provider meets standard-of-care documentation requirements.

What a Telehealth Visit Covers

A telehealth provider can review your hemoglobin A1c, fasting glucose, liver function tests, and weight history to determine whether pioglitazone is appropriate. Prescribers should screen for contraindications including New York Heart Association Class III or IV heart failure, active bladder cancer, and severe hepatic impairment before initiating therapy. [17]

DEA and Controlled Substance Rules

Pioglitazone is not a controlled substance. It carries no DEA schedule designation, so telehealth providers face no federal or state restriction specific to controlled-substance prescribing when writing a pioglitazone prescription. The prescription can be sent electronically to any Alabama-licensed pharmacy, including mail-order pharmacies. [18]

Clinical Evidence Supporting Pioglitazone Use

Type 2 Diabetes: Glycemic Efficacy

Pioglitazone reduces hemoglobin A1c by 0.5% to 1.4% from baseline in randomized controlled trials. A Cochrane systematic review of thiazolidinediones in type 2 diabetes (2016) confirmed clinically meaningful reductions in A1c versus placebo, with modest weight gain (2 to 4 kg) as the most common adverse effect. [19] The FDA-approved label specifies that pioglitazone is indicated as an adjunct to diet and exercise, not as monotherapy replacing insulin in insulin-dependent patients. [1]

NASH/MASH: PIVENS Trial Data

The PIVENS trial (N=247, NEJM 2010) is the landmark study for pioglitazone in NASH. Pioglitazone 30 mg daily for 96 weeks produced a histologic response (reduction in NASH Activity Score by 2 or more points) in 34% of pioglitazone-treated patients versus 19% of placebo patients (P<0.04). [15] Liver fibrosis did not improve significantly versus placebo, but hepatocellular injury markers fell substantially.

The American Association for the Study of Liver Diseases (AASLD) practice guidance states: "Pioglitazone can be used to treat NASH in patients with or without type 2 diabetes." [20] This guideline endorsement drives a meaningful share of pioglitazone prescriptions written off-label in Alabama gastroenterology and hepatology practices.

Cardiovascular Considerations

The PROactive trial (N=5,238, Lancet 2005) evaluated pioglitazone in patients with type 2 diabetes and existing cardiovascular disease. The primary composite endpoint did not reach statistical significance, but the main secondary endpoint (all-cause mortality, non-fatal myocardial infarction, and stroke) was reduced by 16% with pioglitazone versus placebo (P<0.027). [21] Providers must weigh this potential benefit against pioglitazone's known risk of fluid retention and heart failure exacerbation in susceptible patients.

Bladder Cancer Signal

The FDA added a warning about bladder cancer risk to the pioglitazone label in 2011 based on an interim analysis of a 10-year epidemiologic study. A subsequent meta-analysis (N=over 1.2 million patient-years) found a modest increase in bladder cancer risk with long-term use exceeding 12 months. [22] Prescribers should review patient history for hematuria or prior bladder conditions before initiating therapy.

Savings Programs and Patient Assistance in Alabama

Takeda Patient Assistance Program

Takeda Pharmaceuticals operates a patient assistance program (PAP) for brand-name Actos. Uninsured or underinsured Alabama residents who meet income thresholds (generally at or below 400% of the federal poverty level) may receive Actos at no cost. Applications are submitted through Takeda's patient services line and require income documentation. [23]

NeedyMeds and RxAssist

NeedyMeds and RxAssist maintain databases of manufacturer PAPs, state programs, and charitable programs. Both sites list pioglitazone assistance resources and are updated regularly. Alabama patients who cannot afford generic pioglitazone even at Walmart's $4 price should search these databases for additional resources. [4]

340B Program Pharmacies in Alabama

Alabama federally qualified health centers (FQHCs) and qualifying hospitals participate in the 340B Drug Pricing Program, which allows covered entities to purchase outpatient drugs at significantly reduced prices and pass savings to patients. Several Alabama health systems including UAB Health and DCH Health System hold 340B eligibility. Patients receiving care at these facilities may access pioglitazone at near-zero cost. [24]

How Alabama Compares to Neighboring States

Generic pioglitazone pricing is largely consistent across the Southeast because it reflects national wholesaler contracts. Tennessee and Georgia retail pharmacies show similar cash prices of $10 to $18 per month. Mississippi Medicaid covers pioglitazone as a non-preferred agent requiring PA, mirroring Alabama's approach. Florida Medicaid similarly restricts pioglitazone to non-preferred status. [6]

The key differentiator for Alabama patients is the state's active 503A compounding pharmacy sector and the expanded telehealth access under the 2021 Telehealth Act, both of which give Alabama residents more options to access pioglitazone at lower cost than simple retail pricing might suggest.

Safety Monitoring Requirements

Baseline Labs Before Starting

Before prescribing pioglitazone, providers should obtain a complete metabolic panel (CMP) to assess hepatic function, a baseline A1c, and a urinalysis to screen for hematuria. [17] The FDA label recommends against initiating pioglitazone in patients with ALT greater than 2.5 times the upper limit of normal. [1]

Ongoing Monitoring

Patients on pioglitazone should have liver enzymes checked if symptoms of hepatic dysfunction develop. Weight and edema should be assessed at each visit. Women taking pioglitazone for more than one year may face a modestly increased risk of bone fractures, particularly at the distal radius, humerus, and fibula. The ADA Standards of Care note this fracture risk and recommend calcium and vitamin D optimization. [8]

Drug Interactions

CYP2C8 inhibitors such as gemfibrozil can increase pioglitazone plasma concentrations by up to five-fold, raising the risk of fluid retention and hypoglycemia when combined with insulin or a sulfonylurea. [25] CYP2C8 inducers such as rifampin can reduce pioglitazone exposure. Pharmacists at Alabama retail pharmacies routinely screen for these interactions at the point of dispensing.

Dosing Reference for Alabama Prescribers and Patients

The FDA-approved dose range for pioglitazone in type 2 diabetes is 15 mg to 45 mg once daily. The PIVENS trial used 30 mg daily for the NASH indication. Dose adjustments are not required for renal impairment, which makes pioglitazone useful in patients with diabetic kidney disease who cannot tolerate metformin. [1] The drug should be taken with or without food, at the same time each day.

Patients starting at 15 mg can titrate to 30 mg after 8 to 12 weeks if glycemic response is inadequate and the drug is tolerated. A further titration to 45 mg is permitted but carries higher rates of fluid retention. Patients with active or a history of congestive heart failure should not receive doses above 15 mg without cardiology input. [17]